Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.

Journal of the National Comprehensive Cancer Network : JNCCN - 30 Jun 2021

Wang Chongkai, Fakih Marwan

Abstract excerpt

Dual HER2-targeted therapy has been associated with clinical responses and prolonged progression-free survival and overall survival in RAS-wild type HER2-amplified colorectal cancer (CRC). However, no clinical benefits have been reported in patients with CRC with HER2 mutations. Activated HER2 mutations have been largely deemed resistant to trastuzumab and to dual HER2 targeting. This report describes a patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Lapatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 34214965
DOI: 10.6004/jnccn.2021.7023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.PMID 34214965Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseSemantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read ↗

HER2 activating mutations are targets for colorectal cancer treatment.Semantic proximity Read ↗

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAFSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an<i>ERBB2</i>S310F MutationSemantic proximity Read ↗

HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.Semantic proximity Read ↗

Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.Semantic proximity Read ↗

Targeting HER2 expression in cancer: New drugs and new indications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.